WallStSmart

Novartis AG ADR (NVS)vsSemler Scientific Inc (SMLR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 131544% more annual revenue ($56.58B vs $42.98M). NVS leads profitability with a 23.9% profit margin vs 0.9%. SMLR trades at a lower P/E of 5.0x. SMLR earns a higher WallStSmart Score of 53/100 (C-).

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 4.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.96

SMLR

Buy

53

out of 100

Grade: C-

Growth: 5.3Profit: 3.5Value: 8.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$109.60

Current Price

$147.85

$38.25 premium

UndervaluedFair: $109.60Overvalued
SMLRUndervalued (+43.5%)

Margin of Safety

+43.5%

Fair Value

$35.98

Current Price

$20.33

$15.65 discount

UndervaluedFair: $35.98Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$282.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

SMLR3 strengths · Avg: 10.0/10
P/E RatioValuation
5.0x10/10

Attractively priced relative to earnings

Price/BookValuation
0.8x10/10

Reasonable price relative to book value

EPS GrowthGrowth
3570.1%10/10

Earnings expanding 3570.1% YoY

Areas to Watch

NVS4 concerns · Avg: 3.0/10
PEG RatioValuation
2.484/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

SMLR4 concerns · Avg: 2.8/10
Market CapQuality
$348.27M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.2%3/10

ROE of 0.2% — below average capital efficiency

Profit MarginProfitability
0.9%3/10

0.9% margin — thin

Revenue GrowthGrowth
-0.4%2/10

Revenue declined 0.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bull Case : SMLR

The strongest argument for SMLR centers on P/E Ratio, Price/Book, EPS Growth.

Bear Case : NVS

The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.

Bear Case : SMLR

The primary concerns for SMLR are Market Cap, Return on Equity, Profit Margin. Thin 0.9% margins leave little buffer for downturns.

Key Dynamics to Monitor

NVS profiles as a declining stock while SMLR is a value play — different risk/reward profiles.

SMLR carries more volatility with a beta of 1.33 — expect wider price swings.

SMLR is growing revenue faster at -0.4% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

SMLR scores higher overall (53/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Semler Scientific Inc

HEALTHCARE · MEDICAL DEVICES · USA

Semler Scientific, Inc. develops, manufactures, and markets proprietary products that help healthcare providers evaluate and treat patients with chronic conditions in the United States. The company is headquartered in Santa Clara, California.

Want to dig deeper into these stocks?